Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
190.16
+0.61 (+0.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
928,130
Open
188.22
Bid (Size)
190.16 (1)
Ask (Size)
190.36 (2)
Prev. Close
189.55
Today's Range
187.94 - 191.19
52wk Range
181.31 - 268.30
Shares Outstanding
144,000,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
October 17, 2024
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and...
Via
Benzinga
Topics
Workforce
Exposures
Layoff
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
October 16, 2024
Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans...
Via
Benzinga
Exposures
Product Safety
Performance
YTD
-28.97%
-28.97%
1 Month
-3.76%
-3.76%
3 Month
-16.01%
-16.01%
6 Month
-2.17%
-2.17%
1 Year
-26.09%
-26.09%
More News
Read More
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
October 14, 2024
Via
Benzinga
Large-Cap Stocks In Trouble - Sunday, Oct. 13
October 13, 2024
Via
Talk Markets
The Latest Analyst Ratings For Biogen
October 10, 2024
Via
Benzinga
Looking Into Biogen's Recent Short Interest
October 03, 2024
Via
Benzinga
Forecasting The Future: 20 Analyst Projections For Biogen
September 23, 2024
Via
Benzinga
Key Takeaways From Biogen Analyst Ratings
September 04, 2024
Via
Benzinga
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
October 10, 2024
Via
MarketBeat
Topics
ETFs
Earnings
Exposures
Financial
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
October 09, 2024
From
Biogen Inc.
Via
GlobeNewswire
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
October 08, 2024
Via
Benzinga
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
October 08, 2024
From
Biogen Inc.
Via
GlobeNewswire
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
October 07, 2024
Via
Benzinga
Exposures
Product Safety
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
September 28, 2024
Via
The Motley Fool
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
September 26, 2024
Via
Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
September 24, 2024
Via
Benzinga
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
September 24, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Board Appoints Two New Independent Directors
September 12, 2024
From
Biogen Inc.
Via
GlobeNewswire
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
September 09, 2024
Via
Benzinga
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
September 09, 2024
Via
Benzinga
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
September 09, 2024
Via
Benzinga
Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder
September 04, 2024
Via
Benzinga
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
September 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
August 31, 2024
Via
The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
August 28, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.